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a b s t r a c t
Tumor growth is not only dictated by events involving tumor cells, but also by the environment they
reside in, the so-called tumor microenvironment (TME). In the TME, cancer-associated fibroblasts
(CAFs) are often the predominant cell type. CAFs were long considered to be of limited importance in
the TME, but are now recognized for their pivotal role in cancer progression. Recently, it has become evi-
dent that different subsets of CAFs exist, with certain CAF subtypes having protumorigenic properties,
whereas others show more antitumorigenic characteristics. Currently, the intricate interaction between
the different subsets of CAFs with tumor cells, but also with immune cells that reside in the TME, is still
poorly understood. This crosstalk of CAFs with tumor and immune cells in the TME largely dictates how a
tumor responds to therapy and whether the tumor will eventually be eliminated, stay dormant or will
progress and metastasize. Radiotherapy (RT) is a widely used and mostly very effective local cancer treat-
ment, but CAFs are remarkably RT resistant. Although radiation does cause persistent DNA damage, CAFs
do not die upon clinically applied doses of RT, but rather become senescent. Through the secretion of
cytokines and growth factors they have been implicated in the induction of tumor radioresistance and
recruitment of specific immune cells to the TME, thereby affecting local immune responses. In this review
we will discuss the versatile role of CAFs in the TME and their influence on RT response.
 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
For decades cancer research has mainly been focused on cell
intrinsic mechanisms of carcinogenesis, especially after the discov-
ery of tumor suppressor genes and oncogenes [1]. However,
already in 1889 the ‘‘seed and soil” hypothesis was proposed by
Stephen Paget suggesting that elements of the stroma were impor-
tant for tumor development [2]. He suggested that metastasis is
not due to random events, but rather that some tumor cells (the
‘‘seeds”) grow preferentially in selected organs (the ‘‘soil”) and that
metastases only appear when the appropriate seed was implanted
in its suitable soil. This hypothesis is now confirmed by an exten-
sive body of experimental research and clinical data [3]. There has
been an appreciable increase in our understanding of the crosstalk
that occurs between malignant cells and their organ microenviron-
ment on the molecular, cellular and systemic level [3]. The variety
of immune cells, stromal cells such as fibroblasts and pericytes,
secreted factors, extracellular matrix (ECM) proteins and the vas-
culature in the tumor forms the so-called tumor microenviron-
ment (TME) [4] (Fig. 1A). The TME does not only influence tumor
cell proliferation, invasion andmetastasis of cancer cells, angiogen-
esis, regulation of immune cell infiltration and the immune
response, but also has an impact on the therapy response [5]. We
here discuss the cellular and molecular cross talk between cells
in the TME and radiotherapy response with a special focus on can-
cer associated fibroblasts (CAFs).
2. Cancer-Associated Fibroblasts
Fibroblasts can be considered as the weeds of the body, as they
can survive harsh conditions that usually kills other cells. Because
they can survive severe stress, including chemotherapy and radio-
therapy, CAFs may represent a resistant cell type that can actively
contribute to tumor relapse [6]. CAFs are recognized to be of criti-
cal importance in cancer progression [7–9], and in multiple solid
tumors the presence of CAFs has been associated with poor prog-
nosis [10]. CAFs are a prominent cell type in the TME and, next
to cancer cells, constitute the majority of cell populations present
in many solid cancers, including head and neck squamous-cell car-
cinoma (HNSCC), where late-stage HNSCC for example frequently
consists of up to 80% of CAFs [11–13]. CAFs can originate from var-
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ious cell types including resident fibroblasts, bone marrow-derived
mesenchymal cells, adipocytes, endothelial cells and stellate cells
[14]. This can differ between stages of tumor initiation and pro-
gression, but also between tumor types [14–16]. In multiple solid
tumors the intratumoral CAF population consists of different sub-
sets that can respond differently to a variety of stromal stimuli, dis-
play distinctive secretory phenotypes and execute specific
biological functions in the TME [17–26]. Currently, there is not
yet a universal nomenclature used for the different subsets, but
ongoing efforts for this are emerging [27]. CAFs or their specific
subsets are generally characterized by expression of a-smooth
muscle actin (a-SMA), Fibroblast activation protein-a (FAP), S100
calcium-binding protein A4 (S100A4 or FSP1) and Platelet-
derived growth factor receptor alpha/beta (PDGFRa/b). Many of
these markers are, however, also present on normal (activated)
fibroblasts or other cells types [6,17,28,29], but together with the
absence of epithelial, endothelial and immune cell markers such
as Platelet endothelial cell adhesion molecule (PECAM-1 or
CD31), cytokeratin and CD45 (Protein tyrosine phosphatase, recep-
tor type, C), CAFs can be identified [13,17,30].
In the TME, CAFs have been demonstrated to influence many
aspects of tumor biology. Most studies describe CAFs as producers
of cytokines, chemokines, enzymes, metabolites and ECM (extra-
cellular matrix) molecules [14]. Interestingly, CAFs are often found
to have pro-tumorigenic properties by secreting growth factors
(e.g vascular endothelial growth factor (VEGF), epidermal growth
factor (EGF) and insulin-like growth factor (IGF), cytokines
(e.g Interleukin (IL)-6, tumor-necrosis factor alpha (TNF-a) and
Transforming Growth Factor beta (TGF-b) and chemokines
(e.g. C-X-C motif chemokine (CXCL) 1, CXCL2 and CXCL12) foster-
ing tumor growth [31–36]. Other reports, however, have also
attributed anti-tumorigenic characteristics to them; for example,
they are suggested to form a physical barrier to restrict tumor cell
growth and migration [37], and targeting the stroma can lead to
immunosuppression, angiogenesis and worse survival [38–40].
CAFs are also known to be actively involved in the generation of
desmoplasia; the growth of fibrous or connective tissue [41,42]. In
the TME, CAFs are the major cell type responsible for the synthesis
of ECM proteins such as collagens, laminin, tenascin C, fibronectin,
but also many matrix metallopeptidases (MMPs) [6,43]. Interest-
ingly, many immunosuppressive signaling molecules (e.g. VEGF
and TGF-b) are matrix-bound and can be liberated from the ECM
through MMPs [44,45], thus in addition to being secreted by CAFs,
also the release of immunosuppressive molecules from the ECM
mediated by CAF-secreted MMPs can contribute to the immuno-
suppressive TME. CAFs thus play a key role in remodeling the
ECM. While the matrix architecture has long been considered to
simply provide the structural framework of connective tissues, it
is now recognized that it plays a key role in cancer cell survival
and proliferation [46] and in facilitating or suppressing antitumor
immune surveillance [47]. By remodeling the ECM, CAFs can also
contribute to the increased mechanical stress that is generated in
the TME, which can lead to compression of blood and lymphatic
vessels, reduction of the perfusion rate and thus drug delivery,
but also induction of hypoxia, promoting a more aggressive cancer
phenotype [27,48].
Because CAFs can produce many different cytokines, chemoki-
nes, growth factors, ECM molecules, metabolites, miRNAs and exo-
somes they can influence cancer cells as well as other cells present
in the TME, including immune cells (Fig. 1B).
3. CAFs and tumor cells
The interplay between cancer and stromal cells in the TME is
recognized as a major driver of tumor progression and metastasis
[49]. System-wide analyses have shed light on the complex
tumor-fibroblast interactions that are involved in tumorigenicity
[50]. This bilateral interaction of CAFs and tumor cells can oppose,
but also synergize each other’s function [14,28]. Especially the
Fig. 1. Cancer Associated Fibroblasts in the Tumor Microenvironment and therapy response A) CAFs play a central role in the TME by interacting with cancer cells and
immune cells and affecting key processes such as B) immunomodulation, metabolism, ECM remodeling, autophagy, epithelial-mesenchymal transition and treatment
resistance to e.g. C) radiation therapy. Different factors expressed by CAFs after RT mediate subsequent fibrosis, EMT/invasion and treatment resistance [126,131–133].
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paracrine signaling between CAFs and cancer cells, where CAFs
produce different growth factors, chemokines and cytokines, can
lead to tumor growth, cancer invasion and metastasis [14,33,51–
57]. The crosstalk between cancer cells and CAFs in the TME also
leads to metabolic reprogramming that contributes to activation
of CAFs and cancer progression [58]. Interestingly, CAFs have been
shown to co-travel with tumor cells in the blood [59]. By bringing
their own ‘‘soil” cancer cells facilitate their own survival and
extravasation to metastatic sites [59]. After the uptake of tumor-
derived exosomes also resident fibroblasts can be involved in
preparing a premetastatic niche [60] and vice-versa CAF-derived
exosomes are able to reprogram the metabolic machinery of tumor
cells and enhance tumor growth by transferring metabolites,
including amino acids, lipids and TCA-cycle intermediates to tumor
cells [61].
4. CAFs and immune cells
Initially, it was believed that cancer immune evasion was
dependent on cancer cells, however increasing evidence shows
that also CAFs can fuel immune escape in the TME [44]. CAFs can
use a wide range of mechanisms to alter the anti-tumor immune
response. They can affect the anti-tumor immune response by i)
influencing the recruitment of immune cells, ii) drive an immuno-
suppressive function in, in particular, immune cells, iii) remodel
the ECM to induce an immunosuppressive microenvironment
and iv) directly inhibit the killing by cytotoxic lymphocytes [62].
Hereby CAFs can attract, retain and affect multiple immune subsets
into the TME, including macrophages, Dendritic cells (DCs), Mye-
loid Derived Suppressor cells (MDSCs), Natural Killer (NK) cells
and different subsets of T cells. Emerging evidence now support
the hypothesis that this is not a unidirectional effect. Tumor infil-
trating immune cells can also alter the stromal compartment,
emphasizing a high degree of crosstalk between stromal and
immune cells [63].
4.1. Macrophages
In the TME, macrophages and especially the subset of M2
macrophages are described to be major drivers of a tumor-
supporting and immunosuppressive environment in tumors,
including activation of stromal cells [63,64]. Synergistically, CAFs
and tumor associated macrophages have been associated with
prognostic significance in multiple types of cancer [65–68]. Cell-
cell interaction between these two cell types can induce the
recruitment and activation of each other, and their combined activ-
ities contribute to tumor progression [68]. By secretion of CXCL12,
Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) and
IL-6, CAFs can actively polarize resident macrophages towards the
more protumorigenic M2-phenotype [67,69,70]. Reciprocally,
TAMs with a M2 phenotype further activate CAFs and thereby pro-
mote tumor progression [71].
It has also been postulated that via the modification of the ECM
CAFs can influence the presence of macrophages in the TME. CAFs
are able to synthesize ECM components such as collagen type I, II
and IV, but they can also express proteases like FAP, which by
cleaving type I collagen alters ECM composition. It has been
demonstrated that macrophages are not able to attach to native
collagen type I, but they can bind to FAP-cleaved collagen type I
through the scavenger receptors they express on their surface
[72]. The expression of FAP was positively correlated to the num-
ber of macrophages in the tumor stroma [72]. Thus, by modifying
the ECM CAFs enhance the recruitment and retention of macro-
phages in the TME and probably potentiating their biological func-
tions. Overall, the interaction of CAFs and TAMs seems to be
reciprocal and triggered by cancer cells to favor the establishment
of an immunosuppressive microenvironment.
4.2. Dendritic cells
DCs are the most important antigen-presenting cells that have a
pivotal role in activation of T cell-mediated anti-tumor immunity.
It has been reported that hepatic carcinoma derived CAFs induce
Indoleamine 2,3-dioxygenase (IDO)-producing, regulatory DCs,
thereby inducing higher number of T regulatory (Treg) cells, result-
ing in a decreased anti-tumor response [73]. CAFs are also a major
producer of TGF-b [51,74]. TGF-b can affect DC development, activ-
ity and motility and in general DCs acquire a regulatory phenotype
in the presence of TGF-b [75–77]. Fibroblast-produced IL-6 is
reported to favor the differentiation of monocytes into tumor asso-
ciated macrophages at the expense of differentiation into DCs [78].
IL-6 however also directly influences DC function; IL-6-mediated
activation of the Signal transducer and activator of transcription
3 (STAT3) pathway affects DC maturation, disabling T cell activa-
tion and subsequently inducing T cell anergy and immune toler-
ance [79–81]. Next to IL-6 and TGF-b, CAFs also produce VEGF
[82,83]. This may not only affect angiogenesis, but may also alter
DC function as VEGF has been shown to suppress its generation
and maturation [84–86].
4.3. Myeloid Derived Suppressor Cells
MDSCs form a heterogeneous population of immature myeloid
cells that suppress T cell function and promote tumor angiogene-
sis, tumor progression and metastasis [87,88]. By secreting factors
such as CXCL12, IL-6 and chemokine (C–C motif) ligand 2 (CCL2),
CAFs have been shown to drive differentiation of monocytes into
MDSC as well as attract them to the TME [89–91]. Recently it has
been shown that CAFs can also promote immunosuppression by
inducing Reactive Oxygen Species (ROS) -generating monocytic
MDSC in lung squamous cell carcinoma [92].
4.4. Natural Killer cells
NK cells are innate immune cells that have cytotoxic effector
functions [93]. CAFs can modulate the activation of NK cells in
the tumor stroma. CAFs derived from endometrial cancer have
been shown to significantly reduce NK killing activity by direct
cell-to-cell contact [94]. Compared to normal fibroblasts, CAFS
have a lower expression of the Poliovirus receptor (PVR/CD155),
which is a ligand for the NK activating receptor DNAX Accessory
Molecule-1 (DNAM-1). By downregulating CD155, CAFs attenuate
NK cell-killing activity [94]. Also, Prostaglandin E2 (PGE2) and
MMPs released from CAFs significantly impairs the ability of NK
cells to recognize and kill tumor cells [95–97]. CAFs can thus inhi-
bit the activity of NK cells against tumor development directly
through cell-to-cell contact and indirectly by the secretion of sol-
uble factors [93,98].
4.5. T Cells
The interaction between CAFs and T cells has been demon-
strated by multiple studies in vivo and in vitro. Distinct subpopula-
tions of CAFs have been shown to exhibit immunosuppressive
functions through affecting attraction, survival, migration, function
and differentiation of different subsets of T cells in multiple types
of cancer [18,99–102]. CAFs can do this by secretion of different
cytokines and chemokines such as IL-6, CXCL12 and IL-1b, by the
release of nitric oxid (NO), but also by expression of molecules such
as OX40-ligand (OX40L), Programmed death ligand 2 (PD-L2),
Junctional adhesion molecule B (JAM2), B7H3, Dipeptidyl
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peptidase-4 (DPP4) and ecto-50-nucleotidase (CD73) [18,99–102].
Interestingly, CAFs have also been demonstrated to express MHCII
molecules [20,103] a characteristic of antigen presenting cells
(APCs). Via expression of MHCII molecules together with the
expression of costimulatory molecules such as CD80 and CD86,
professional APCs can activate T cells and initiate an antigen-
specific immune response. MHCII expression in the absence of
expression of costimulatory molecules leads to activation of Tregs
and thus to suppression of an immune response. As CAFs typically
do not express costimulatory molecules [20,103] it suggests that
CAFs induce activation of Tregs. Also normal colonic myofibrob-
lasts have been shown to express MHCII and this expression was
essential for the induction of Tregs. The authors postulate that in
the normal colon the colonic myofibroblasts contribute to the sup-
pression of active inflammation by supporting expansion of Tregs
[104].
Localization and migration of T cells is dependent on the speci-
fic tissue architecture; in loose fibronectin there is active T cell
motility, whereas T cells migrate poorly in dense matrix areas
[105]. The composition of the ECM can thus influence antitumor
immunity by controlling the positioning and migration of T cells
[106]. By remodeling the ECM, also CAFs can influence T cell migra-
tion and trap T cells in the stroma by forming a physical barrier
limiting access to tumor cells [44,107,108]. CAFs can also affect T
cell function and activation by the release of the ECM protein
big-h3. The presence of big-h3 reduces antigen-specific activation
and proliferation of CD8 + T cells [109]. Interestingly, CXCL12
secreted by FAP-expressing CAFs has also been suggested to pre-
vent effector T cells from reaching cancer cells. CXCL12 secreted
by CAFs localized on cancer cells and when the ligand for CXCL12,
(chemokine (C-X-C motif) receptor 4 (CXCR4)), was inhibited, T
cells accumulated again to the tumor [110]. The immunosuppres-
sive effect of CAFs may thus be partly mediated via CXCL12-
mediated T cell exclusion from the tumor.
CAFs directly isolated from multiple human tumors are shown
to express the PD-1 ligands PD-L1 and PD-L2 [107,111,112], sug-
gesting direct suppression of T cells. Another way how CAFs can
suppress T cells is via the production of metabolites such as adeno-
sine and lactate [113,114].
Taken together, this demonstrates the role of CAFs as important
inhibitors of T effector mediated immune responses against tumors
and simultaneously as potent activators of Treg functions.
5. CAFs and radiotherapy
Radiotherapy (RT) is an effective and widely used local cancer
treatment, with a majority of cancer patients undergoing RT at
one point during treatment. Although primarily directed at killing
tumor cells, RT also affects the TME, including the immune cells,
endothelial cells, vasculature and fibroblasts, with important con-
sequences for tumor growth, -dissemination, and -control. RT is
given in different doses and treatment fractions based on tumor
type as well as to reduce normal tissue toxicity. How these differ-
ent treatment schedules influence the TME is, however, largely
unknown. Many different mechanisms have been described
whereby RT via the TME, and in particular CAFs, influences tumor
growth and treatment sensitivity.
CAFs are particularly radioresistant as they do not die upon RT,
but rather go into senescence [115,116]. Indeed, irradiation of CAFs
has been shown to cause persistent DNA damage [116,117], and to
induce a senescence response [116,117] and specific changes in the
secretory profile (e.g. CXCL12, TGF-b1, IGF-1, IGFBP2 and NO)
[117–125]. Notably, RT-mediated TGF-b signaling induces activa-
tion of (peri)tumoral fibroblasts to CAFs and their proliferation in
the TME, which enhances the CAF mediated effects on the tumor.
The altered phenotype of the CAFs subsequently induces an altered
metabolic profile [121], and is associated with epithelial-to-
mesenchymal transition [118] and changes in invasiveness
[118,119] of the associated tumor cells. This plethora of RT-
induced changes in the interaction between tumor cells, immune
cells, and the TME has particular consequences for the tumor’s sen-
sitivity for treatment.
6. CAFs and sensitivity to RT
RT can induce antitumor immune responses, although in gen-
eral this does not lead to the much-desired abscopal effect where
the RT-induced immune response has systemic effects on distant
metastases. The generally immunosuppressive TME may counter
the RT-induced immune response. As mentioned above, RT also
promotes activation of CAFs and thus modulates the behavior of
the TME for the response to RT (Fig. 1C) [126]. After RT, the TME
activates a number of pathways and mechanisms that may subse-
quently be associated with tumor radioresistance, which can be
through secretion of cytokines, growth factors, exosomes, and
ECM remodeling factors [127,128]. The interactions between
fibroblasts/ CAFs and cancer cells are bi-directional and promote
tumor growth, cancer invasion, metastasis, and therapy resistance
[129,130].
For example, by the activation of inflammatory pathways, RT
induces fibrosis by different cytokines such as TGF-b1, TNF-a, IL-
1, IL-4 and IL-13; chemokines such as MCP-1 and MIP-1b; angio-
genic and growth factors [131–133]. Fibrosis in turn is associated
with radioresistance by supplying signals to tumor cells leading
to treatment resistance, proliferation and metastasis [134]. Addi-
tionally, activated CAFs can induce epithelial-to-mesenchymal
transition [118], which may promote radioresistance via loss of
e-cadherin [135]. Similarly, RT induces expression of both a and
b integrins within the stroma [136,137]. This increased integrin
expression induces chemoradiation resistance of tumors and
induces tumor growth of multiple cancer types [138,139]. Further-
more, radiation resistance of prostate cancer cells could be linked
to the loss of the membrane protein caveolin-1 in stromal fibrob-
lasts [140–142]. Furthermore, in vivo CAFs can induce autophagy
and subsequent irradiated tumor cell recovery [128]. Autophagy
is either directly involved in radioresistance by modulating DNA
damage repair [143] or indirectly by enabling cells to survive
hypoxia [144], thereby inducing radioresistance.
Fibroblasts have been found to secrete exosomes containing 50-
triphosphate RNA to induce an IFN-related DNA damage resistance
gene signature (IRDS) by activating RIG-1. Subsequent activation of
STAT1 facilitated Notch signaling in breast cancer cells inducing a
RT resistant stem cell-like phenotype [145]. This IRDS and STAT1
signaling have found to be associated with radioresistant breast
cancer in vitro, in vivo and in patient cohorts [146,147]. Similarly,
after multiple passages of the head and neck cancer cell line SCC-
61 in irradiated mice, these became radioresistant. The resulting
resistant SCC-61 cells exhibited the same IRDS in which STAT1
was demonstrated to be a key mediator of radioresistance [148].
Of note, Steer et al. tested the effect of different fibroblasts
(NIH-3 T3 or L929) on several tumor cell lines in direct or indirect
coculture, and found complex bi-directional direct and indirect
interactions between cancer cells and fibroblasts with impact on
tumor growth and therapy outcome. They found that the impact
of fibroblasts on tumor cells radiation response largely depended
on the fibroblast and tumor cell type, the culture conditions (di-
rect/indirect co-culture) and the respective endpoint (short-term
vs. long-term; in vitro vs. in vivo [149]. This is likely caused by
the fact that tumor cells and RT influence fibroblast phenotypes,
with important repercussions for the reciprocal interaction
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between CAFs and tumor cells, which makes interpretation of
many, especially preclinical, experimental data difficult.
7. Perspectives
Although CAFs have long been ignored in cancer biology, their
essential role has received more attention the last decade. CAFs
affect multiple steps in cancer development, progression, metasta-
sis and (radio)therapy response and are therefore a promising tar-
get in cancer therapy. However, general depletion of CAFs is likely
not a good strategy for enhancing cancer therapy response, as pro-
tumorigenic as well as anti-tumorigenic properties are ascribed to
them. This is evidenced by the contradictory results found when
targeting the tumor stroma [14,32,38,39,134,150]. For CAF target-
ing to become a viable option, the specificity of markers to identify
CAFs and their heterogeneity should be considered. Currently, sev-
eral preclinical strategies are ongoing that target specific actions or
subpopulations of CAFs [17,44,86]. Additionally, radiotherapy
schedules that enhance anti-tumorigenic and/or attenuate protu-
morigenic functions of CAFs and immune cells may be identified,
thereby enhancing radiosensitivity of solid tumors. Future studies
that further decipher the complex tripartite interaction between
CAFs, cancer cells and immune cells will provide a more solid base
for the design of more effective (combinatorial) therapeutic strate-
gies against cancer.
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